1-3 of 3
Michael Shi, MD PhD
Close
Sort by
Journal Articles

Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the Phase II Sustain Study

Darla K Liles, MD, Rodolfo Cançado, Julie Kanter, MD, Abdullah Kutlar, MD, Andreas Bruederle, Michael Shi, MD PhD, Federico Campigotto, Kenneth I. Ataga
Journal: Blood
Blood (2018) 132 (Supplement 1): 1082.
https://doi.org/10.1182/blood-2018-99-112201
Published: 2018
Journal Articles

Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study

Julie Kanter, MD, Abdullah Kutlar, MD, Darla Liles, Rodolfo Cançado, Andreas Bruederle, Michael Shi, MD PhD, Zewen Zhu, Kenneth I Ataga, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 613.
https://doi.org/10.1182/blood.V130.Suppl_1.613.613
Published: 2017
Journal Articles

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Christof Scheid, MD, PhD, Donna Reece, Meral Beksac, MD, Andrew Spencer, MD, Natalie Callander, MD, Pieter Sonneveld, MD, Ghulam Kalimi, PhD, Can Cai, Michael Shi, MD, PhD, Jeffrey W. Scott, A. Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 4055.
https://doi.org/10.1182/blood.V120.21.4055.4055
Published: 2012